Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia - reply.
作者信息
Cancado Rodolfo Delfini, Friedrisch João Ricardo
机构信息
Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
出版信息
Hematol Transfus Cell Ther. 2020 Jan-Mar;42(1):100-101. doi: 10.1016/j.htct.2019.01.007. Epub 2019 Apr 30.
Abstract
摘要
相似文献
1
Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia - reply.静脉注射羧麦芽糖铁治疗缺铁性贫血——回复
Hematol Transfus Cell Ther. 2020 Jan-Mar;42(1):100-101. doi: 10.1016/j.htct.2019.01.007. Epub 2019 Apr 30.
2
Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.静脉注射羧基麦芽糖铁在缺铁性贫血孕妇中的作用
J Nepal Health Res Counc. 2017 Sep 8;15(2):96-99. doi: 10.3126/jnhrc.v15i2.18158.
3
Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.羧基麦芽糖铁静脉注射与标准护理用于术后贫血管理的比较：一项前瞻性、开放标签、随机对照试验
Lancet Haematol. 2016 Sep;3(9):e415-25. doi: 10.1016/S2352-3026(16)30078-3. Epub 2016 Aug 4.
4
Ferric carboxymaltose: a review of its use in iron deficiency.三价羧基麦芽糖铁：缺铁治疗的研究进展。
Drugs. 2015 Jan;75(1):101-27. doi: 10.1007/s40265-014-0332-3.
5
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.铁羧基麦芽糖铁或葡萄糖酸亚铁治疗炎症性肠病患者的低磷血症发生率。
Aliment Pharmacol Ther. 2019 Aug;50(4):397-406. doi: 10.1111/apt.15386. Epub 2019 Jul 2.
6
Ferric Carboxymaltose: A Review in Iron Deficiency.三价羧基麦芽糖铁：缺铁症治疗药物评价
Drugs. 2018 Mar;78(4):479-493. doi: 10.1007/s40265-018-0885-7.
7
Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.系统评价与网络荟萃分析：比较不同静脉用铁剂治疗炎症性肠病患者缺铁性贫血的疗效和耐受性。
Aliment Pharmacol Ther. 2017 May;45(10):1303-1318. doi: 10.1111/apt.14043. Epub 2017 Mar 21.
8
Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia.成本最小化分析表明，对于结肠癌合并缺铁性贫血患者，术前治疗采用静脉注射羧基麦芽糖铁优于蔗糖铁或口服铁剂。
Technol Health Care. 2016;24(1):111-20. doi: 10.3233/THC-151074.
9
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.孕期静脉注射羧麦芽糖铁治疗缺铁和缺铁性贫血
Arch Gynecol Obstet. 2018 Jul;298(1):75-82. doi: 10.1007/s00404-018-4782-9. Epub 2018 May 8.
10
Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.法国慢性心力衰竭伴缺铁患者静脉注射羧基麦芽糖铁的预算影响。
ESC Heart Fail. 2019 Jun;6(3):559-569. doi: 10.1002/ehf2.12432. Epub 2019 Apr 25.
引用本文的文献
1
Clinical, economical and safety impact of ferric carboxymaltose use in Patient Blood Management programme in Portuguese National Health Service hospitals.在葡萄牙国家卫生服务医院的患者血液管理计划中使用羧基麦芽糖铁的临床、经济和安全影响。
Sci Rep. 2022 Nov 11;12(1):19335. doi: 10.1038/s41598-022-21929-3.
本文引用的文献
1
Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.CONFIRM-HF研究的原理与设计：一项双盲、随机、安慰剂对照研究，旨在评估静脉注射羧基麦芽糖铁对慢性心力衰竭伴缺铁患者功能能力的影响。
ESC Heart Fail. 2014 Sep;1(1):52-58. doi: 10.1002/ehf2.12006.
2
Ferric carboxymaltose: a review of its use in iron deficiency.三价羧基麦芽糖铁：缺铁治疗的研究进展。
Drugs. 2015 Jan;75(1):101-27. doi: 10.1007/s40265-014-0332-3.
3
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.FIND-CKD：一项针对慢性肾脏病合并缺铁性贫血患者比较静脉注射羧麦芽糖铁与口服铁剂的随机试验。
Nephrol Dial Transplant. 2014 Nov;29(11):2075-84. doi: 10.1093/ndt/gfu201. Epub 2014 Jun 2.
4
Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study.对疲劳缺铁女性单次注射羧基麦芽糖铁的评估——PREFER一项随机、安慰剂对照研究。
PLoS One. 2014 Apr 21;9(4):e94217. doi: 10.1371/journal.pone.0094217. eCollection 2014.
5
A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).一项比较静脉注射异麦芽糖铁 1000 治疗（Monofer）与口服铁剂治疗 IBD 贫血的随机、开放标签、非劣效性研究（PROCEED）。
Am J Gastroenterol. 2013 Dec;108(12):1877-88. doi: 10.1038/ajg.2013.335. Epub 2013 Oct 22.
6
A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.一项多中心、随机、阳性药物对照研究，旨在评估静脉注射羧甲麦芽糖铁治疗缺铁性贫血患者的疗效和安全性。
Transfusion. 2014 Feb;54(2):306-15. doi: 10.1111/trf.12289. Epub 2013 Jun 17.
7
Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.三价羧麦芽糖铁可预防炎症性肠病患者贫血复发。
Clin Gastroenterol Hepatol. 2013 Mar;11(3):269-77. doi: 10.1016/j.cgh.2012.10.013. Epub 2012 Oct 16.
8
Intravenous iron therapy: how far have we come?静脉铁剂治疗：我们已经取得了多大进展？
Rev Bras Hematol Hemoter. 2011;33(6):461-9. doi: 10.5581/1516-8484.20110123.
9
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.FERGIcor 研究：一项评估羧基麦芽糖铁治疗炎症性肠病缺铁性贫血的随机对照试验
Gastroenterology. 2011 Sep;141(3):846-853.e1-2. doi: 10.1053/j.gastro.2011.06.005. Epub 2011 Jun 12.
10
Diagnosis and management of iron deficiency anemia in patients with IBD.炎症性肠病患者铁缺乏症的诊断和治疗。
Nat Rev Gastroenterol Hepatol. 2010 Nov;7(11):599-610. doi: 10.1038/nrgastro.2010.151. Epub 2010 Oct 5.
Zotero 插件